SERVIZI DI TELEMEDICINA - LINEE GUIDA

In G.U. n. 256 del 2 novembre 2022 è pubblicato il Decreto 21 settembre 2022 del Ministero della salute: Approvazione delle linee guida per i servizi di telemedicina - Requisiti funzionali e livelli di servizio.

The Charter of Trieste: Accessibility to services for all persons - an update in 2022

 

Back in 2020 SCImPULSE Foundation had the honour to join forces with the Italian National Health Institute, the Autonomous Region Friuli-Venezia-Giulia, and Federsanità ANCI FVG in initiating and launching the Charter of Trieste. We had originally planned to run a 2 years campaign to receive feedbacks and EoI and to hold a new meeting during ESOF2022 in Leiden to update the Charter and trace a new trajectory for the future. As we all know, the covid pandemics happened and changed many priorities across EU in healthcare and service accessibility studies, and if we didn't have the opportunity to campaign, we certainly had a lot of learning and reflection opportunities.
So, here we are today, discussing where do we stand, and what's in store for the future of accessibility design for all.

Data Driven and Model Based Computational Futures in Cardiovascular Practice - A call for papers with Frontiers in Cardiovascular Medicine

 

Die Blutgefasse Des Menschen (1898), an antique lithograph of the human blood vessels and cardiovascular system. Digitally enhanced from the original plate. - Licensed as CC BY 2.0 by Rawpixel Ltd

Manuscript submission is now open for a new article collection we are co-editing called “Data Driven and Model Based Computational Futures in Cardiovascular Practice” with Frontiers in Cardiovascular Medicine (Impact Factor 5.846, CiteScore 8.2) - and we wanted you to be among the first to know.
 
The collection aims to bring together the latest quality articles on the strengths and weaknesses of both data-driven and model-based approaches, in a scientific domain with huge clinical and humanitarian impact. We hope to focus on the state of the art and adjacent futures of diagnoses, forecasting, and personalization of interventions in cardiovascular medicine. We especially wish to receive submissions by authors invested in bridging the two worlds to ensure that the best of each is at the service of patients, caregivers and the healthcare system. As an expert in the field and given your previous publications, we feel your research would strengthen the collection. 
We welcome clinical trials, hypothesis & theory and original research articles. Case reports are invited, especially around near-miss/failures and dealing with ethical pitfalls, but will also be considered when proposing evidence directly relevant to future developments. Technology & code will be considered when particularly novel or of great potential impact in cardiovascular medicine. Policy & practice reviews may also be considered if authorship involves large communities or relevant political or supragovernmental Institutions. 
Frontiers in Cardiovascular Medicine’s average review time from submission to final decision is 67 days. All accepted papers will be published Open Access and made available to the community immediately upon acceptance - they are also indexed in PubMed.
 
The deadline for manuscript submissions is 7 December 2022, but we can accommodate extensions on a case-by-case basis. If you would like some feedback on your manuscript’s suitability - please submit a preliminary abstract by 7 October. 
 
The Frontiers editorial team will send a follow-up email soon with further details about submitting with them. As you certainly know, Frontiers is a gold open access publisher and fees apply, which you can find out about here. However, it is our pleasure to stress that an extensive list of Institutions and Funding Agencies have signed partnership agreements with Frontiers, which might apply in your case, and you may want to check here. Should you not be affiliated to any of the partner institution, and not have sufficient funding to cover the fees, Frontiers has a fee support policy you might want to consult here.
 
I hope that you will be happy to contribute! If you are interested, please register via the link below. 
 
Kind regards on behalf of
Marco Manca (SCImPULSE Foundation)
Arrigo Francesco Giuseppe Cicero (University of Bologna)
Roman Bauer (University of Surrey)

"-omics sciences" and "deep learning and the future of care" are now public (but in Italian only, for the time being)

 You might remember our announcement from a few months ago about our partners' contribution to the Master ARTE (artificial intelligence and telemedicine) of the University of Parma.

The lectures contributed then as part of the program have been held under embargo to give enrolled students a reasonable advance access to content... However they are now offered to everyone in keeping with our spirit. We are glad to share the videos here below for your evaluation:

1) -omics sciences

2) Deep Learning and the future of care

Lowering barriers to bottom-up innovation and collaboration is more important than optimizing perfomances/efficiency

I have recently read this twitter post by John Carlos Baez and immediately something else came to my mind: the piece "The counter-intuitive rise of Python in scientific computing" arguing that if one tool (python in the specific case) feels arguably technically inferior to alternatives, especially in the hands of power users, then we must still reckon with the fact that it has become the de facto most common/popular language in scientific computing and data sciences. How is this possible, despite remaining quite puzzling to technicians, is a secret hidden in plain sight: we are talking of a tool that enormously lowers the barriers to access, and makes it rather easy to focus on exploration, reuse, and composition of preexisting work, despite at the cost of some performances and elegance, thus attracting all those users whose mission is not to specifically challenge and develop tools, but to use them in applied fields with their own very specialised knowledge/expertise to be kept up to date and integrated.

How is this interesting to us in ISOMERISM? We have to learn to navigate the proper shades of interdisciplinary collaboration if we are to be successful in the digitalisation of medicine. Technical elegance and performance optimisation should be the focus of those elements of the value chain that can 1) be relegated to the infrastructures, hiding away the need for hardcore specialised skills from users AND 2) be relegated to those elements of the value chain whose uncertainty within the system is limited/nihil (e.g. execution of computation, I/O, data preservation, energy optimisation, ...)

All other layers (more visible to the human stakeholders, whether care givers or patients) should be progressively more and more nuanced in the negotiation between technology focus and users' freedom, embracing the necessity to accept sub-optimality in order to accomodate uncertainty and evolution... and failure of the system, with the ensuing social actions needed to correct the trajectory. Composability and reuse, with low entry barriers, become a priority in such a sociotechnical infostructure, as success is not definable as technical compliance, but only evaluated on the meaning of the results produced by the interactions emerging within and around the system.

The EU Commission has usually favoured highly technical agendas, however some initiatives (i.e. PerMedCoE ) appear to have captured the gist of the reflection I just shared, at least judging by their early ventures, bringing fresh air in the landscape of platforms development for medicine... we will follow them to learn more, hoping to have found new allies

Meaningful human control of autonomous systems

A few days ago Dr Marco Manca joined an online informal seminar/conversation hosted by the Edgeryders about the topic of meaningful human control of autonomous systems, largely inspired by Dr Manca's contribution to the activities of NATO STO HFM-330 but touching on the wider issues of how to understand current machine learning and the potentials and pitfalls of its deployment across most sectors of human enterprise.

We believe this might be of interest to many, and we are pleased to hereby share a recording of the meeting. We further invite you to join the conversation online hosted by the Edgeryders

SCImPULSE Foundation presented about Deep Learning adoption in healthcare at ARTE!

You might already know that our parent entity, the Italian Society of Telemedicine, is patronizing the 1st level Master on ARtificial intelligence and TElemedicine "ARTE" hosted by the University of Parma.

Today, the Board of Directors of SCImPULSE Foundation decided to overreach, and each member of the Board offered a lecture on the subject, from the point of view of their unique professional expertise... what's even better, they decided to license it under the Creative Commons "Attribution" 4.0 licence, so we are able to share the recordings with you, and really anyone interested:

Digital Twins - from industrial management to healthcare practice by SCImPULSE CTO, Taghi Aliyev

citable referring to DOI 10.5281/zenodo.6198812

...and Managing innovation - how to evaluate cost/benefits and plan for the future by SCIMPULSE CFO, Stef Cuijpers

citable referring to DOI 10.5281/zenodo.6198797

We hope you enjoyed listening to them as much as we did, and we would like to extend them the thanks of our community, for taking their time to condensate and share a bit of their hard-earned wisdom!